M onoallelic mutations within several Fanconi anemia complementation group genes, including FANCD1/BRCA2, FANCJ/BRIP1, FANCO/RAD51C, and FANCN/PALB2, confer a moderate to high risk for breast cancer (BC) and/or ovarian cancer (OC), [1] [2] [3] while the role of other Fanconi anemia-associated genes in BC and/or OC pathogenesis remains elusive. Among those genes, FANCM (OMIM 609644) is a plausible candidate because the FANCM protein and its binding partner FAAP24 (OMIM 610884) are essentially required to anchor the multi-subunit Fanconi anemia core complex to chromatin after DNA damage. 4 Sofar ,2truncat-ing germline variants within the FANCM gene, c.5101C>T (p.GIn1701Ter [rs147021911]) and c.5791C>T (p.Arg1931Ter
[rs144567652]), have been associated with an increased BC risk.
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A study in the Finnish population revealed the nonsense variant c.5101C>T to be associated with familial BC. 6 Because all studies described to date rely on only 2 truncating germline variants, mutational analysis of the entire coding region of the FANCM gene in patients and geographically matched controls is pending. Moreover, a higher cumulative number of patients known to carry truncating FANCM mutations is required to establish genotype-phenotype correlations, especially regarding the TNBC tumor phenotype and cancer site.
Methods
In the course of a whole exome sequencing approach, we identified the c.5101C>T germline mutation in a BRCA1 and BRCA2-negative familial BC index case from a high-risk family of German origin, which prompted us to analyze the FANCM gene in detail. The mutation was also present in the affected mother and maternal aunt, both affected by BC (eFigure in the Supplement). Based on the whole exome sequencing data provided by the Exome Aggregation Consortium, 0.65% of more than 22000 individuals of non-Finnish European origin carried heterozygous loss-of-function (LoF) mutations within the FANCM gene (excluding The Cancer Genome Atlas data; eTable 1 in the Supplement). To assess the cumulative CF of FANCM in the German population, we analyzed the whole exome sequencing data of a cohort of 2187 independent individuals not enriched for cancer phenotypes. Concordant with the data provided by the Exome Aggregation Consortium, 11 in 2187 controls carried heterozygous germline LoF mutations, resulting in a cumulative CF of 0.50% (eTable 1 in the Supplement).
Between May 1, 2016, and July 1, 2016, we analyzed the entire coding region of the FANCM gene in a well-characterized cohort of 2047 BRCA1 and BRCA2-negative familial index patients with BC of German origin by focusing on LoF alterations. Family history was considered positive when the inclusion criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for genetic germline testing are fulfilled (eTable 2 in the Supplement).
Written informed consent was obtained from all patients, and ethical approval was given by the Ethics Committee of the University of Cologne.
Results
Overall, 21 in 2047 index cases carried heterozygous truncating FANCM mutations, resulting in a cumulative CF of 1.03% (OR, 2.05; 95% CI, 0.94-4.54; P = .049), as compared with the whole exome sequencing data from German controls (Table) . A total of 1547 (76%) in 2047 patients were affected by BC and reported no personal or family history of OC. Among these 1547, we identified truncating mutations in 16 patients, resulting in a cumulative mutation frequency of 1 
Discussion
Screening the entire coding sequence of the FANCM gene revealed its weak but overall significant association with familial BC. The study established an association between FANCM and early-onset BC disease in familial index cases. In addition, it confirmed an association of heterozygous LoF mutations within the FANCM gene with the TNBC tumor phenotype. However, this study focused on familial cases, which may lead to a significant selection bias in determining mutation frequency. For other moderately penetrant risk genes, such as CHEK2, it has been demonstrated that ORs are higher in familial than in unselected BC cases.
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Thus, it might be worthwhile to analyze unselected BC cases and then stratify for early-onset BC or TNBC. Moreover, additional studies will be required in larger sample sets to establish a potential role of FANCM mutations in OC pathogenesis. Nevertheless, based on the present analyses and previously published findings, 5-7 we recommend including FANCM in diagnostic gene panel testing. 
